Metraipolis › archive › dc_da4a7e362e7d
Improving type 2 diabetes polygenic risk scores by incorporating rare, low-frequency, and population-specific variants — Europe PMC PPR:PPR1127248
- Source
- Europe PMC
- Original
- https://europepmc.org/article/PPR/PPR1127248
- DOI
- 10.1101/2025.11.24.25340878
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-06T08:49:44.207Z
- SHA-256 of the archived text
0821cb65b5cc98d0445117dbc7ff8c056ca69cf8206af9fd134485dc58a18789- Stable URL of this page
https://metraipolis.com/documento/dc_da4a7e362e7d
How to cite
Improving type 2 diabetes polygenic risk scores by incorporating rare, low-frequency, and population-specific variants — Europe PMC PPR:PPR1127248 — Europe PMC, https://europepmc.org/article/PPR/PPR1127248 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_da4a7e362e7d (Metraipolis archive dc_da4a7e362e7d, sha256 0821cb65b5cc98d0445117dbc7ff8c056ca69cf8206af9fd134485dc58a18789)
BibTeX
@misc{dcda4a7e362e7d,
title = {Improving type 2 diabetes polygenic risk scores by incorporating rare, low-frequency, and population-specific variants — Europe PMC PPR:PPR1127248},
howpublished = {Europe PMC},
url = {https://europepmc.org/article/PPR/PPR1127248},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_da4a7e362e7d; sha256 0821cb65b5cc98d0445117dbc7ff8c056ca69cf8206af9fd134485dc58a18789},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC, https://europepmc.org/article/PPR/PPR1127248. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Polygenic risk scores (PRSs) can improve type 2 diabetes (T2D) risk prediction beyond clinical risk factors, but most exclude low-frequency, rare, and population-specific variants. We hypothesized that incorporation of rare variants via large-scale, well-imputed or whole-genome sequence-based genome-wide association (GWAS) meta-analyses and expanded linkage disequilibrium (LD) reference panels would improve risk prediction for T2D. We constructed a GWAS meta-analysis (230,675 T2D cases and 991,401 T2D controls), enabling the inclusion of rare variants (minor allele frequency [MAF] range= 1×10 −5 - 0.01) to construct three T2D PRSs: (i) CTSLEB, which utilizes a custom ancestry-matched LD panel of 79.5 million variants and 83K participants to specifically model LD of rare variants; (ii) PRS-CS (TAGIT), using a reference panel expanded to 2.3 million variants to better capture low-frequency and population specific variants (population-specific MAF ≥ 0.01); (iii) PRS-CS (HM3), using a standard LD panel with HapMap3 variants (1.2 million variants). Performance was evaluated in the All of Us Research Program (20,301 T2D cases; 30,617 T2D controls) and compared to a benchmark multi-ancestry PRS (MAF≥0.01), developed by the D-PRISM consortium and derived from a significantly larger set of ancestry-specific meta-analyses (totaling 359,891 T2D cases and 1,825,792 controls). Expanding variant coverage with PRS-CS (TAGIT) and CTSLEB improved risk prediction relative to PRS-CS (HM3). While PRS-CS (TAGIT) showed greater prediction accuracy in the overall population, CTSLEB uniquely captured risk driven by rare variants, showing greater prediction accuracy for carriers of rare and low-frequency variants compared to PRS-CS (TAGIT) (AUC = 0.832 vs. 0.823 p(DeLong test) = 7.9×10 −5 ) and PRS-CS (HM3) (AUC = 0.832 vs 0.818, p(DeLong test) = 2.39×10 −7 ). The benchmark D-PRISM PRS showed the highest predictive performance for all ancestries except in African ancestry populations, where CTSLEB performed similarly for the overall population (CTSLEB AUC = 0.786 vs. D-PRISM AUC = 0.784, p(DeLong test) = 0.57) and significantly better for rare variant carriers (CSTLEB AUC = 0.775 vs. D-PRISM AUC = 0.768, p(DeLong test) = 8.71×10 −3 ). These results demonstrate the value in incorporating rare and population-specific variants into PRS construction, improving genetic risk prediction in diverse populations. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: medRxiv, 2025 (prima pubblicazione 2025-11-28). Identificativi: DOI 10.1101/2025.11.24.25340878. Pagina: https://europepmc.org/article/PPR/PPR1127248 — https://doi.org/10.1101/2025.11.24.25340878. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-06T08:20:26.534Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.